Anti-IL6 Agents (Tocilizumab, Siltuximab) in COVID19 IL-6 activates T cells and macrophages, among other cell types (see “Cytokine Activation Syndrome” IL-6 levels are reported to correlate with severe COVID-19 Tocilizumab 4-8mg/kg (suggested dose 400mg) IV x1 (anti-IL6R mAb) Dose can be repeated 12h later if inadequate response to the first dose. Total dose should be no more than 800mg. Tocilizumab should not be administered more than twice. Common adverse effects include: - Transaminitis (AST, ALT) > 22% - Infusion reaction 4-20% - Hypercholesterolemia 20% - Upper respiratory tract infection 7% - Neutropenia 2-7% Alternative: Siltuximab 11mg/kg IV x1 (anti-IL6 mAb) #AntiIL6 #Tocilizumab #Siltuximab #COVID19 #Pharmacology #Management #Medications
